ADC Therapeutics SA (ADCT) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lifecore Biomedical (LFCR) has outperformed ADC Therapeutics SA (ADCT) over the past year, losing 4.5% versus a loss of 67.1%. Over five years, LFCR leads with a -34.4% price change compared with -94.4% for ADCT. Lifecore Biomedical is the larger company by market cap ($243.9 million vs $206.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | LFCR |
|---|---|---|
| Share price | $1.62 | $6.44 |
| Market cap | $206.82M | $243.92M |
| 1-day change | +14.08% | -0.08% |
| YTD return | -59.77% | -21.27% |
| 1-year return | -67.05% | -4.45% |
| 5-year return | -94.42% | -34.35% |
| EPS (TTM) | $-0.60 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $8.98 |
| 52-week low | $0.78 | $3.63 |
| Distance from 52-week high | -67.47% | -28.34% |
| Analyst consensus | none | hold |
| Avg. price target upside | +105.56% | -2.41% |
| Average volume | 1.35M | 289.19K |
| Shares outstanding | 127.67M | 37.91M |
| Employees | 188 | 382 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFCR has outperformed ADCT by 62.6 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
ADCT vs LFCR FAQ
Which is bigger, ADC Therapeutics SA or Lifecore Biomedical?
Lifecore Biomedical (LFCR) is larger, with a market capitalization of $243.92M compared with $206.82M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADCT or LFCR?
LFCR returned -4.45% over the past 12 months, compared with -67.05% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and Lifecore Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.